ArticleAnnals of surgical oncology2025
Genomic and Clinical Predictors of Conversion in Initially Unresectable Colorectal Cancer Liver Metastases.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diversion ostomy improves treatment tolerance, conversion surgery, and survival compared with self-expanding metal stenting in initially unresectable obstructive colorectal cancer.Frontiers in oncology · 2026Article
- A Multimodal MRI-Based Model for Colorectal Liver Metastasis Prediction: Integrating Radiomics, Deep Learning, and Clinical Features with SHAP Interpretation.Current oncology (Toronto, Ont.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundColorectal cancer liver metastases (CRLM) present significant treatment challenges, requiring multimodal conversion therapies. Identifying factors that influence treatment outcomes is crucial for improving clinical management. PATIENTS AND
methodsThis retrospective cohort study included 286 patients with synchronous CRLM who underwent conversion therapies on the basis of sequencing results. Patients were categorized into successful conversion therapy group (SCTG) and failed conversion therapy group (FCTG). Clinical factors and genomic mutations were analyzed for associations with therapy outcomes and survival.
resultsAmong the patients, 106 (37.1%) achieved successful conversion (SCTG), while 180 (62.9%) failed (FCTG). Compared with SCTG, patients in the FCTG had significantly larger metastatic lesions, higher preoperative mesenteric lymph node positivity, and elevated carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels. Six genes (FAT, BRAF, SERPINA3, GRIN2A, ERBB2, and ALK) showed the highest mutation frequency differences in FCTG, correlating with worse outcomes. Any of these mutations was associated with shorter overall survival compared with wild-type patients. A nomogram model using tumor mutation status, CEA, CA19-9, lesion diameter ≥ 5 cm, and positive lymph nodes at diagnosis predicted conversion efficacy (area under the curve = 89.6, 95% confidence interval 22.6-92.4). An extended conversion-related clinical risk score scoring system incorporating these factors effectively stratified poor prognosis populations, serving as a prognostic tool for patients with unresectable CRLM.
conclusionsGenomic profiling improves precision management of CRLM, facilitating tailored conversion strategies and better prognostic prediction. Future studies should validate these findings in prospective cohorts to refine personalized treatment for patients with initially unresectable CRLM.
Indexed as
Identifiers
40659890What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.